Long-term efficacy of canakinumab in the treatment of Schnitzler syndrome
Authors:
- 1 June 2020
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 145 (6) , 1681-1686.e5
Abstract
No abstract availableFunding Information
- Novartis Pharma
This publication has 9 references indexed in Scilit:
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic DiseaseNew England Journal of Medicine, 2017
- Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled studyJournal of Allergy and Clinical Immunology, 2017
- The role of interleukin-1 beta in the pathophysiology of Schnitzler’s syndromeArthritis Research & Therapy, 2015
- Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: A french multicenter studyAutoimmunity Reviews, 2014
- Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndromeAnnals of the Rheumatic Diseases, 2013
- Schnitzler's syndrome: diagnosis, treatment, and follow‐upAllergy, 2013
- The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the ageArthritis Research & Therapy, 2013
- Efficacy and safety of the interleukin‐1 antagonist rilonacept in Schnitzler syndrome: an open‐label studyAllergy, 2012
- Dysfunctional inflammasome in Schnitzler's syndromeRheumatology, 2009